• About
  • Privacy Policy
  • Terms Of Use
  • Contact
Monday, October 2, 2023
Pharma Info Nepal
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
  • Pharmacy Books
  • Pharmacy Notes
No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
  • Pharmacy Books
  • Pharmacy Notes
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Downloads

Nepal Medical Council COVID-19 Treatment Guidelines

Nepal Medical Council COVID-19 Treatment Guidelines

Nabin Bista by Nabin Bista
May 14, 2021
in Downloads, Notice
0
Nepal Medical Council COVID-19 Treatment Guidelines
920
VIEWS
Share on FacebookShare on Twitter

Nepal Medical Council COVID-19 Treatment Guidelines

Nepal Medical Council COVID-19 Treatment Guidelines

Management of Patients during Shortage Created by COVID–19 Surge

Personal Protective Equipment (PPE): 

During the shortage created by COVID–19 surge, use of PPE including N95 respirators, gowns and face covers should be extended between COVID–19 patients and reused following standard guidelines for reuse. 

Oxygen supplementation and Ventilators:

Oxygen supplementation is an important life–sustaining measure for hypoxemic patients. Ensuring sufficient supply of oxygen to admitted patients is the responsibility of hospitals and the state. During oxygen shortage, the following steps are recommended as crisis management.

  • Start therapeutic oxygen supplementation only when SpO2 <90% on room air or patient is dyspneic at rest with SpO2 <92% on room air. The goal of SpO2 saturation should be 92-94%.
  • In patients with chronic lung disease, such as COPD, oxygen supplement should begin when SpO2 is <88% on room air. The target SpO2 should be 88–92%.

Therapeutics 

During the period of shortage, drugs should be reserved and administered to those who are likely  to benefit the most. Based on this principle, the following recommendations are made.

Antivirals and immunomodulators:

  • Remdesivir should be preserved for those with severe discase who are within the first 10 days from symptom onset, but have rapidly progressing hypoxia in spite of systemic corticosteroid use, or for immunocompromised patients requiring low flow oxygen, or severe infection requiring ICU admission who are not on ventilators.
  • Antivirals have not been shown to improve mortality outcomes but only shown to decrease the length of hospitalization.
  • Remdesivir has not been shown to improve outcome in patients who are on ventilators.
  • Tocilizumab: Tocilizumab may be considered, when available, in patients with severe or critical COVID–19, who have rapidly increasing oxygen needs and systemic inflammation despite use of systemic corticosteroids.

Convalescent Plasma (CP): 

  • Convalescent plasma therapy is NOT recommended in hospitalized patients with COVID-19.
  • There is insufficient evidence to recommend for or against convalescent plasma in  ambulatory patients with mild or moderate COVID-19.

Systemic Corticosteroids:

Start corticosteroids early when SpO2 is less than 93% on room air. During surge and lack of available beds, start oral corticosteroids in outpatient settings when SpO2<93%. Options of corticosteroids are oral Dexamethasone 6 mg OD or Prednisolone 40 mg OD or oral Methylprednisolone 32 mg OD, depending on availability. When starting corticosteroids in outpatient setting, ensure follow up in the form of tele–consultation or in person  follow up at “fever” clinic within 2–3 days to decide on duration of steroid therapy. Admit patient when SpO2 <90% on room air despite initiation of corticosteroid therapy. Systemicn corticosteroids should NOT be started in mild or moderate disease when SpO2 is >93%. 3d)

Inhaled Corticosteroids:

For adults with mild to moderate disease, within 7 days from onset of symptoms, inhaled budesonide 800 micrograms twice a day may be considered. The treatment can be discontinued upon resolution of symptoms, or if patient is started on systemic steroids.

Antibiotics:

Empiric antibiotic therapy in the absence of clear evidence of bacterial infection is  NOT recommended.


Notice to all Physicians and Health Professionals 

COVID–19 pandemic has caused a huge crisis in our health care system and it is our duty to contribute as professionals and individuals in saving lives and minimizing suffering of our people. 

Please be rational in prescribing drugs: Remdesivir, Steroids and antibiotics. 

NOT every patient with covid needs them and or benefits them. Please refer to NMC guidelines on management of COVID–19 for exact indications and contraindications. 

Tocilizumab is not currently available in Nepal and is not registered yet. Please hold off prescribing it until it is available in Nepal, so that patients and families don’t suffer unncesaarily. 

COVID-19 Triage/Management Algorithm for PHC 

Objectives: 

The purpose of this guideline is to help health care professionals in primary health care centers/setting, during the COVID–19 pandemic surge, to: 

  • Triage suspected or proven COVID cases,
  • Manage moderate COVID cases in their centers
  • Recognize severe cases and refer appropriately after initial stabilization
  • Comply with appropriate infection control measures when managing COVID-19 cases

Target group: Physicians, nurses, other healthcare providers involved in management of COVID-19 infection in the Primary Health Care Centers of Nepal.

 



  • DDA Notice Regarding False and Misleading Propaganda of Medicines
  • How Vaccines are Developed?
  • Pulse Oximeter and Its Use 


Download PDF

 

 

Tags: GuidelinesMedicine InformationPharmacist
Previous Post

How Vaccines are Developed?

Next Post

DDA Notice for the Production, Import and Sale of Sanitizers in Nepal

Nabin Bista

Nabin Bista

Hello, Thank You for visiting my blog I am Nabin Bista, Dedicated and self motivated young Pharmacist from Nepal. Blogging is my passion. I am studying B Pharmacy at Institute of Medicine - IOM. If you want me to write about any posts that you found confusing/difficult, please mention in the comments below.

Related Posts

Nepal Pharmacy Council 23rd Name Registration Exam Application Form Notice

Nepal Pharmacy Council 23rd Name Registration Exam Application Form Notice

August 1, 2023
Nepal Pharmacy Student's Society Conducting GMP Training for Pharmacy Students

NPSS Conducting GMP Training for Pharmacy Students

July 26, 2023
Aspartame Possibly Carcinogenic to Humans

Aspartame Possibly Carcinogenic to Humans

July 21, 2023
List of ICH Guidelines

List of ICH Guidelines

June 29, 2023
Load More
Next Post
Department of Drug Administration (DDA) Notice for the Production, Import and Sale of Sanitizers in Nepal

DDA Notice for the Production, Import and Sale of Sanitizers in Nepal

Discussion about this post

Recommended

Pharmacology Facts Every Pharmacist Should Know

Pharmacology Facts Every Pharmacist Should Know

2 years ago
Vacancy Announcement Livecare Pharmaceuticals 

Vacancy Announcement Livecare Pharmaceuticals 

3 years ago

Don't Miss

List of Antibiotics Not Recommended by WHO

List of Antibiotics Not Recommended by WHO

September 17, 2023
“Pharmacy strengthening health systems” is the theme of World Pharmacists Day 2023

“Pharmacy strengthening health systems” is the theme of World Pharmacists Day 2023

September 14, 2023
Vacancy Announcement for Assistant Pharmacist Gandaki Province

Vacancy Announcement for Assistant Pharmacist Gandaki Province

August 19, 2023
Vacancy Announcement Assistant Pharmacist Hetauda Hospital 

Vacancy Announcement for Assistant Pharmacist Hetauda Hospital 

August 12, 2023

About Pharma Info Nepal

Pharma Info Nepal (Nabin’s Blog) was initiated in 2019 with the aim of providing relevant and accurate information for pharmacy, nursing and other health professionals. Since then it is conveying health related educational and informational updates of Nepal. It serves as a source for learning materials on diverse topics relating to medicine intended basically for pharmacy and nursing students. It covers job opportunities, question collections for pharmacy license, nursing license as well as various competitive exams.

Our readers rely on us for the well referenced and latest updates collected from the reliable sites.

Follow us

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

Information Reader

Contents (text, image, graphics, documents and other materials) published on this portal are collected from other relevant sources with the sole purpose of sharing information. Contents and features are subject to change and all rights reserved to Pharma info Nepal. The information presented on this web portal and its official social media handles have no affiliation to any organization that author is involved with either professionally or personally.

If you have found anything displayed incorrectly or have further suggestions on improving our effort, please do not hesitate to reach out at pharmainfonepal1@gmail.com !
We hope you find Pharma info Nepal a helpful site. Thanks !!!

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Pharmacy Notes
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • About
  • Privacy Policy
  • Terms Of Use
  • Contact

© 2021 Nabin's Blog

No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
  • Pharmacy Books
  • Pharmacy Notes

© 2021 Nabin's Blog

error: